Mycenax Biotech - Asset Resilience Ratio
Mycenax Biotech (4726) has an Asset Resilience Ratio of 0.04% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Mycenax Biotech balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Mycenax Biotech's Asset Resilience Ratio has changed over time. See Mycenax Biotech (4726) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Mycenax Biotech's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 4726 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$1.20 Million | 0.04% |
| Total Liquid Assets | NT$1.20 Million | 0.04% |
Asset Resilience Insights
- Limited Liquidity: Mycenax Biotech maintains only 0.04% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Mycenax Biotech Industry Peers by Asset Resilience Ratio
Compare Mycenax Biotech's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Mycenax Biotech (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Mycenax Biotech.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.25% | NT$8.50 Million ≈ $267.80K |
NT$3.37 Billion ≈ $106.12 Million |
-3.72pp |
| 2023-12-31 | 3.97% | NT$149.62 Million ≈ $4.71 Million |
NT$3.77 Billion ≈ $118.79 Million |
+3.58pp |
| 2022-12-31 | 0.39% | NT$17.32 Million ≈ $545.55K |
NT$4.45 Billion ≈ $140.29 Million |
+0.12pp |
| 2021-12-31 | 0.27% | NT$8.50 Million ≈ $267.80K |
NT$3.14 Billion ≈ $98.90 Million |
+0.20pp |
| 2020-12-31 | 0.07% | NT$1.20 Million ≈ $37.81K |
NT$1.75 Billion ≈ $55.22 Million |
-5.95pp |
| 2019-12-31 | 6.02% | NT$84.76 Million ≈ $2.67 Million |
NT$1.41 Billion ≈ $44.36 Million |
-2.79pp |
| 2018-12-31 | 8.81% | NT$98.60 Million ≈ $3.11 Million |
NT$1.12 Billion ≈ $35.25 Million |
-13.48pp |
| 2017-12-31 | 22.30% | NT$292.69 Million ≈ $9.22 Million |
NT$1.31 Billion ≈ $41.36 Million |
-- |
About Mycenax Biotech
Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company's services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-drug c… Read more